Abstract
Dermatomyositis is distinctive among the family of idiopathic inflammatory myopathies as patients display a characteristic set of skin manifestations. The cutaneous findings, which can be subdivided into active lesions or those resulting from scarring, occur in particular anatomic distributions. In this chapter, the skin manifestations of dermatomyositis are discussed including facial erythema, “heliotrope” rash, “V sign,” “shawl sign,” “Gottron’s papules,” “Gottron’s sign,” “holster sign,” “mechanic’s hands,” “ragged” cuticles with nailfold changes, and calcinosis cutis. This chapter will also highlight the prevalence of these findings within the various myositis subtypes. An understanding of the protean cutaneous features of dermatomyositis is essential to accurately diagnose and treat this autoimmune disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Armadans-Tremolosa I, Selva-O'Callaghan A, Visauta-Vinacua B, Guilera G, Pinal-Fernandez I, Vilardell-Tarres M. Health-related quality of life and Well-being in adults with idiopathic inflammatory myopathy. Clin Rheumatol. 2014;33(8):1119–25.
Hundley JL, Carroll CL, Lang W, Snively B, Yosipovitch G, Feldman SR, et al. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol. 2006;54(2):217–20.
Goreshi R, Chock M, Foering K, Feng R, Okawa J, Rose M, et al. Quality of life in dermatomyositis. J Am Acad Dermatol. 2011;65(6):1107–16.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–7.
Uribe L, Ronderos DM, Diaz MC, Gutierrez JM, Mallarino C, Fernandez-Avila DG. Antisynthetase antibody syndrome: case report and review of the literature. Clin Rheumatol. 2013;32(5):715–9.
Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum. 2008;58(2):571–6.
Ponyi A, Constantin T, Garami M, Andras C, Tallai B, Vancsa A, et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci. 2005;1051:64–71.
Mautner GH, Grossman ME, Silvers DN, Rabinowitz A, Mowad CM, Johnson BL Jr. Epidermal necrosis as a predictive sign of malignancy in adult dermatomyositis. Cutis. 1998;61(4):190–4.
Mahe E, Descamps V, Burnouf M, Crickx B. A helpful clinical sign predictive of cancer in adult dermatomyositis: cutaneous necrosis. Arch Dermatol. 2003;139(4):539.
Shimizu M, Ueno K, Ishikawa S, Yokoyama T, Kasahara Y, Yachie A. Cutaneous calcinosis in juvenile dermatomyositis. J Pediatr. 2013;163(3):921.
Muller SA, Winkelmann RK, Brunsting LA. Calcinosis in dermatomyositis; observations on course of disease in children and adults. AMA Arch Derm. 1959;79(6):669–73.
Weinel S, Callen JP. Calcinosis cutis complicating adult-onset dermatomyositis. Arch Dermatol. 2004;140(3):365–6.
Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47(4):505–11.
Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF. The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69:1909.
Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146(1):26–30.
Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken). 2016;68(5):689–94.
Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1gamma antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449–55.
Kovacs SO, Kovacs SC. Dermatomyositis. J Am Acad Dermatol. 1998;39(6):899–920. quiz 1–2.
Chansky PB, Olazagasti JM, Feng R, Werth VP. Cutaneous dermatomyositis disease course followed over time using the cutaneous dermatomyositis disease area and severity index (CDASI). J Am Acad Dermatol. 2018;79:464–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Chansky, P.B., Werth, V.P. (2020). Clinical Features of Myositis: Skin Manifestations. In: Aggarwal, R., Oddis, C. (eds) Managing Myositis. Springer, Cham. https://doi.org/10.1007/978-3-030-15820-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-030-15820-0_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-15819-4
Online ISBN: 978-3-030-15820-0
eBook Packages: MedicineMedicine (R0)